Ralaniten acetate
Modify Date: 2024-09-17 19:37:16
Ralaniten acetate structure
|
Common Name | Ralaniten acetate | ||
|---|---|---|---|---|
| CAS Number | 1637573-02-4 | Molecular Weight | 436.929 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H29ClO6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Ralaniten acetateA novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer; AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity, and as a result, may affect a broader AR population including mutational and splice variant ARs. Prostate Cancer Phase 2 Clinical |
| Name | Ralaniten acetate |
|---|
| Description | A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer; AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity, and as a result, may affect a broader AR population including mutational and splice variant ARs. Prostate Cancer Phase 2 Clinical |
|---|---|
| References | References 1. Antonarakis ES, et al. Oncologist. 2016 Dec;21(12):1427-1435. View Related Products by Target Estrogen Receptor/ERR Prostate Cancer |
| Molecular Formula | C23H29ClO6 |
|---|---|
| Molecular Weight | 436.929 |